Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ERAS 01.07.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-14
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur ERAS Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.07.2025 - Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.04.2024 - 7th Annual Evercore HealthCONx Conference

Recent Filings

  • 01.15.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
PDF Version

SAN DIEGO,Jan. 07, 2025(GLOBE NEWSWIRE) --Erasca, Inc.(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43rdAnnualJ.P. Morgan Healthcare Conferencebeing held at the Westin St. Francis Hotel in San Francisco,California. Management will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online atErasca.com/events. An archived replay of the event will be available for 30 days following the webcast atErasca.com/events.

About ErascaAt Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com

Source: Erasca, Inc.

Primary Logo

Source: Erasca, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com